Home LiteratureArticle Details
PMID: 10694938 Published · ppublish English Journal Article Review

CD44 cell adhesion molecules.

Molecular pathology : MP ·Vol. 52 ·No. 4 ·1999-08-00 ·Pages 189-96

Goodison S, Urquidi V, Tarin D

Abstract

The CD44 proteins form a ubiquitously expressed family of cell surface adhesion molecules involved in cell-cell and cell-matrix interactions. The multiple protein isoforms are encoded by a single gene by alternative splicing and are further modified by a range of post-translational modifications. CD44 proteins are single chain molecules comprising an N-terminal extracellular domain, a membrane proximal region, a transmembrane domain, and a cytoplasmic tail. The CD44 gene has only been detected in higher organisms and the amino acid sequence of most of the molecule is highly conserved between mammalian species. The principal ligand of CD44 is hyaluronic acid, an integral component of the extracellular matrix. Other CD44 ligands include osteopontin, serglycin, collagens, fibronectin, and laminin. The major physiological role of CD44 is to maintain organ and tissue structure via cell-cell and cell-matrix adhesion, but certain variant isoforms can also mediate lymphocyte activation and homing, and the presentation of chemical factors and hormones. Increased interest has been directed at the characterisation of this molecule since it was observed that expression of multiple CD44 isoforms is greatly upregulated in neoplasia. CD44, particularly its variants, may be useful as a diagnostic or prognostic marker of malignancy and, in at least some human cancers, it may be a potential target for cancer therapy. This review describes the structure of the CD44 gene and discusses some of its roles in physiological and pathological processes.

MeSH Terms
Biomarkers, Tumor/metabolism Cell Adhesion/physiology Humans Hyaluronan Receptors/genetics,physiology Ligands Neoplasm Proteins/metabolism
Chemicals
Biomarkers, Tumor Hyaluronan Receptors Ligands Neoplasm Proteins
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Goodison S
UCSD Cancer Center, University of California, La Jolla 92093-0658, USA.
Urquidi V
Tarin D
References (114)
114 references, click to expand
  1. Correlation of expression of CD44 isoforms and E-cadherin with differentiation in human urothelial cell lines and transitional cell carcinoma.
    Cancer Lett. 1995 Feb 10;89(1):81-7 PMID: 7533658
  2. A novel ligand for CD44 is serglycin, a hematopoietic cell lineage-specific proteoglycan. Possible involvement in lymphoid cell adherence and activation.
    J Biol Chem. 1995 Mar 31;270(13):7437-44 PMID: 7535771
  3. Regulation of CD44-protein 4.1 interaction by Ca2+ and calmodulin. Implications for modulation of CD44-ankyrin interaction.
    J Biol Chem. 1997 Nov 28;272(48):30322-8 PMID: 9374519
  4. Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function.
    J Exp Med. 1997 Dec 15;186(12):1985-96 PMID: 9396767
  5. Identification of CD44 residues important for hyaluronan binding and delineation of the binding site.
    J Biol Chem. 1998 Jan 2;273(1):338-43 PMID: 9417085
  6. Proinflammatory stimuli regulate endothelial hyaluronan expression and CD44/HA-dependent primary adhesion.
    J Clin Invest. 1998 Jan 1;101(1):97-108 PMID: 9421471
  7. Ezrin/radixin/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2.
    J Cell Biol. 1998 Feb 23;140(4):885-95 PMID: 9472040
  8. Over-expression of human CD44s in murine 3T3 cells: selection against during primary tumorigenesis and selection for during micrometastasis.
    Clin Exp Metastasis. 1998 Jan;16(1):83-93 PMID: 9502080
  9. Blockade of metastasis formation by CD44-receptor globulin.
    Int J Cancer. 1998 Mar 16;75(6):919-24 PMID: 9506538
  10. The ankyrin-binding domain of CD44s is involved in regulating hyaluronic acid-mediated functions and prostate tumor cell transformation.
    Cell Motil Cytoskeleton. 1998;39(3):209-22 PMID: 9519902
  11. Co-expression of osteopontin and CD44v9 in gastric cancer.
    Int J Cancer. 1998 Apr 17;79(2):127-32 PMID: 9583725
  12. Coupling of signal transduction to alternative pre-mRNA splicing by a composite splice regulator.
    EMBO J. 1998 May 15;17(10):2904-13 PMID: 9582284
  13. CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells.
    J Cell Physiol. 1998 Jul;176(1):206-15 PMID: 9618160
  14. Identification and functional analysis of the ezrin-binding site in the hyaluronan receptor, CD44.
    Curr Biol. 1998 Jun 4;8(12):705-8 PMID: 9637922
  15. Inhibition of tumor growth in vivo by hyaluronan oligomers.
    Int J Cancer. 1998 Jul 29;77(3):396-401 PMID: 9663602
  16. CD44 variant exon v5 encodes a tyrosine that is sulphated.
    Eur J Biochem. 1998 Jul 1;255(1):74-80 PMID: 9692903
  17. Expression of antisense CD44 variant 6 inhibits colorectal tumor metastasis and tumor growth in a wound environment.
    Cancer Res. 1998 Aug 15;58(16):3719-26 PMID: 9721884
  18. Functional activation of lymphocyte CD44 in peripheral blood is a marker of autoimmune disease activity.
    J Clin Invest. 1998 Sep 15;102(6):1173-82 PMID: 9739051
  19. Engagement of variant CD44 confers resistance to anti-integrin antibody-mediated apoptosis in a colon carcinoma cell line.
    Cell Adhes Commun. 1998 Jun;6(1):21-38 PMID: 9759519
  20. Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells.
    J Cell Physiol. 1998 Nov;177(2):299-312 PMID: 9766527
  21. CD44 isoform-cytoskeleton interaction in oncogenic signaling and tumor progression.
    Front Biosci. 1998 Jul 1;3:d637-49 PMID: 9634539
  22. Clinical implications of anomalous CD44 gene expression in neoplasia.
    Front Biosci. 1998 Jul 1;3:e89-109 PMID: 9634541
  23. The role of hyaluronic acid in intercellular adhesion of cultured mouse cells.
    Exp Cell Res. 1978 Nov;117(1):155-64 PMID: 720401
  24. The gene, MIC4, which controls expression of the antigen defined by monoclonal antibody F10.44.2, is on human chromosome 11.
    Eur J Immunol. 1982 Aug;12(8):659-63 PMID: 7140811
  25. Aggregation of macrophages and fibroblasts is inhibited by a monoclonal antibody to the hyaluronate receptor.
    Exp Cell Res. 1988 Oct;178(2):224-32 PMID: 2458949
  26. A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family.
    Cell. 1989 Mar 24;56(6):1057-62 PMID: 2466575
  27. The hyaluronate receptor is preferentially expressed on proliferating epithelial cells.
    J Cell Biol. 1989 Apr;108(4):1557-65 PMID: 2466850
  28. Identification of mRNA that encodes an alternative form of H-CAM(CD44) in lymphoid and nonlymphoid tissues.
    Immunogenetics. 1990;32(6):389-97 PMID: 2272659
  29. The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells.
    EMBO J. 1991 Feb;10(2):343-8 PMID: 1991450
  30. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells.
    Cell. 1991 Apr 5;65(1):13-24 PMID: 1707342
  31. Acylation of the lymphoma transmembrane glycoprotein, GP85, may be required for GP85-ankyrin interaction.
    J Biol Chem. 1991 Jun 25;266(18):11761-5 PMID: 1828806
  32. Molecular cloning of CD44R1 and CD44R2, two novel isoforms of the human CD44 lymphocyte "homing" receptor expressed by hemopoietic cells.
    J Exp Med. 1991 Jul 1;174(1):1-5 PMID: 2056274
  33. CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines.
    Cancer Res. 1991 Oct 1;51(19):5292-7 PMID: 1717145
  34. Distinct effects of two CD44 isoforms on tumor growth in vivo.
    J Exp Med. 1991 Oct 1;174(4):859-66 PMID: 1919439
  35. Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44.
    Cancer Res. 1991 Dec 15;51(24):6660-7 PMID: 1742741
  36. A cell surface chondroitin sulfate proteoglycan, immunologically related to CD44, is involved in type I collagen-mediated melanoma cell motility and invasion.
    J Cell Biol. 1992 Jan;116(2):521-31 PMID: 1730766
  37. Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin.
    J Cell Biol. 1992 Feb;116(3):817-25 PMID: 1730778
  38. Participation in normal immune responses of a metastasis-inducing splice variant of CD44.
    Science. 1992 Jul 31;257(5070):682-5 PMID: 1496383
  39. CD44H regulates tumor cell migration on hyaluronate-coated substrate.
    J Cell Biol. 1992 Aug;118(4):971-7 PMID: 1380003
  40. Inhibition of tumor growth in vivo with a soluble CD44-immunoglobulin fusion protein.
    J Exp Med. 1992 Aug 1;176(2):623-7 PMID: 1500863
  41. Variant cell lines selected for alterations in the function of the hyaluronan receptor CD44 show differences in glycosylation.
    J Exp Med. 1995 Aug 1;182(2):431-7 PMID: 7543138
  42. Patterns of splice variant CD44 expression by normal human urothelium in situ and in vitro and by bladder-carcinoma cell lines.
    Int J Cancer. 1995 Aug 9;62(4):449-56 PMID: 7543458
  43. CD44 (Pgp-1) inhibits CD3 and dexamethasone-induced apoptosis.
    Blood. 1995 Oct 1;86(7):2672-8 PMID: 7545465
  44. Abnormal retention of intron 9 in CD44 gene transcripts in human gastrointestinal tumors.
    Cancer Res. 1995 Oct 1;55(19):4273-7 PMID: 7545538
  45. N-terminal and central regions of the human CD44 extracellular domain participate in cell surface hyaluronan binding.
    J Immunol. 1995 Oct 15;155(8):3938-45 PMID: 7561101
  46. Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon.
    J Cell Biol. 1995 Feb;128(4):673-85 PMID: 7532175
  47. Chondroitin sulphate composition and structure in alternatively spliced CD44 fusion proteins.
    Biochem J. 1997 Oct 15;327 ( Pt 2):499-506 PMID: 9359422
  48. Widespread expression of chondroitin sulfate-type serglycins with CD44 binding ability in hematopoietic cells.
    J Biol Chem. 1997 Oct 17;272(42):26714-9 PMID: 9334256
  49. Interaction between the adhesion receptor, CD44, and the oncogene product, p185HER2, promotes human ovarian tumor cell activation.
    J Biol Chem. 1997 Oct 31;272(44):27913-8 PMID: 9346940
  50. Requirement for CD44 in activated T cell extravasation into an inflammatory site.
    Science. 1997 Oct 24;278(5338):672-5 PMID: 9381175
  51. Lymph node (but not spleen) invasion by murine lymphoma is both CD44- and hyaluronate-dependent.
    J Immunol. 1995 May 15;154(10):5345-55 PMID: 7537306
  52. CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor.
    Blood. 1995 May 15;85(10):2885-99 PMID: 7537983
  53. Involvement of CD44 variant isoforms in hyaluronate adhesion by human activated T cells.
    Eur J Immunol. 1995 Oct;25(10):2932-9 PMID: 7589094
  54. To metastasize or not? Selection of CD44 splice sites.
    Nat Med. 1995 Jul;1(7):635-7 PMID: 7585142
  55. Differential expression of CD44 splice variants in human pancreatic adenocarcinoma and in normal pancreas.
    Cancer Res. 1995 Dec 1;55(23):5499-503 PMID: 7585621
  56. Unusual retention of introns in CD44 gene transcripts in bladder cancer provides new diagnostic and clinical oncological opportunities.
    J Pathol. 1995 Sep;177(1):11-20 PMID: 7472774
  57. Regulation of CD44 binding to hyaluronan by glycosylation of variably spliced exons.
    J Cell Biol. 1995 Dec;131(6 Pt 1):1623-33 PMID: 8522617
  58. Oncogene-dependent expression of CD44 in Balb/c 3T3 derivatives: correlation with metastatic competence.
    Clin Exp Metastasis. 1996 Jan;14(1):73-82 PMID: 8521619
  59. Targeted disruption of CD44 in MDAY-D2 lymphosarcoma cells has no effect on subcutaneous growth or metastatic capacity.
    J Cell Biol. 1995 Dec;131(6 Pt 2):1849-55 PMID: 8557751
  60. Receptor-ligand interaction between CD44 and osteopontin (Eta-1).
    Science. 1996 Jan 26;271(5248):509-12 PMID: 8560266
  61. Evidence of involvement of CD44 in endothelial cell proliferation, migration and angiogenesis in vitro.
    Int J Cancer. 1996 May 29;66(5):664-8 PMID: 8647630
  62. A cysteine residue located in the transmembrane domain of CD44 is important in binding of CD44 to hyaluronic acid.
    J Exp Med. 1996 May 1;183(5):1987-94 PMID: 8642309
  63. Hyaluronate-independent metastatic behavior of CD44 variant-expressing pancreatic carcinoma cells.
    Cancer Res. 1996 Jul 1;56(13):3134-41 PMID: 8674073
  64. The CD44 proteins in embryonic development and in cancer.
    Curr Top Microbiol Immunol. 1996;213 ( Pt 1):249-69 PMID: 8814991
  65. Does soluble CD44 reflect the clinical behavior of human cancer?
    Curr Top Microbiol Immunol. 1996;213 ( Pt 3):155-66 PMID: 8815003
  66. A splice variant of CD44 expressed in the rat apical ectodermal ridge contributes to limb outgrowth.
    Ann N Y Acad Sci. 1996 Jun 8;785:345-9 PMID: 8702177
  67. Cellular distribution of CD44 gene transcripts in colorectal carcinomas and in normal colonic mucosa.
    J Clin Pathol. 1996 Jun;49(6):482-8 PMID: 8763263
  68. Accelerated immune response in transgenic mice expressing rat CD44v4-v7 on T cells.
    J Immunol. 1996 Mar 15;156(6):2085-94 PMID: 8690896
  69. Trans-acting factors regulate the expression of CD44 splice variants.
    EMBO J. 1996 Aug 1;15(15):4030-9 PMID: 8670907
  70. Role of CD44 in the reaction of vascular smooth muscle cells to arterial wall injury.
    J Clin Invest. 1996 Aug 1;98(3):877 PMID: 8698880
  71. Progressive loss of CD44 gene expression in invasive bladder cancer.
    Am J Pathol. 1996 Sep;149(3):873-82 PMID: 8780391
  72. Solution structure of the link module: a hyaluronan-binding domain involved in extracellular matrix stability and cell migration.
    Cell. 1996 Sep 6;86(5):767-75 PMID: 8797823
  73. CD44/chondroitin sulfate proteoglycan and alpha 2 beta 1 integrin mediate human melanoma cell migration on type IV collagen and invasion of basement membranes.
    Mol Biol Cell. 1996 Mar;7(3):383-96 PMID: 8868467
  74. CD44 protein levels and its biological activity are regulated in Balb/c 3T3 fibroblasts by serum factors and by transformation with the ras but not with the sis oncogene.
    J Cell Physiol. 1996 Nov;169(2):341-9 PMID: 8908201
  75. Analysis of anomalous CD44 gene expression in human breast, bladder, and colon cancer and correlation of observed mRNA and protein isoforms.
    Am J Pathol. 1996 Nov;149(5):1519-30 PMID: 8909242
  76. Induction of fibroblast apoptosis by anti-CD44 antibody: implications for the treatment of fibroproliferative lung disease.
    Am J Pathol. 1996 Nov;149(5):1639-50 PMID: 8909253
  77. Regulated clustering of variant CD44 proteins increases their hyaluronate binding capacity.
    J Cell Biol. 1996 Nov;135(4):1139-50 PMID: 8922392
  78. Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44.
    J Clin Invest. 1996 Nov 15;98(10):2403-13 PMID: 8941660
  79. Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, in B cell chronic lymphocytic leukemia.
    Leukemia. 1997 Jan;11(1):134-41 PMID: 9001429
  80. Interaction between CD44 and osteopontin as a potential basis for metastasis formation.
    Proc Assoc Am Physicians. 1997 Jan;109(1):1-9 PMID: 9010911
  81. CD44 expression in human breast cancer cell lines is related to oestrogen receptor (ER) status and confluency in vitro.
    Biochem Soc Trans. 1997 May;25(2):356S PMID: 9191401
  82. Rapid analysis of distinctive CD44 RNA splicing preferences that characterize colonic tumors.
    Cancer Res. 1997 Aug 1;57(15):3140-4 PMID: 9242440
  83. CD44 activation and associated primary adhesion is inducible via T cell receptor stimulation.
    J Immunol. 1997 Sep 15;159(6):2549-53 PMID: 9300670
  84. Multiple intron retention occurs in tumor cell CD44 mRNA processing.
    Am J Pathol. 1998 Oct;153(4):1221-8 PMID: 9777953
  85. Novel CD44 messenger RNA isoforms in human thyroid and breast tissues feature unusual sequence rearrangements.
    Clin Cancer Res. 1996 Aug;2(8):1251-4 PMID: 9816294
  86. CD44 variant isoforms are essential for the function of epidermal Langerhans cells and dendritic cells.
    Cell Adhes Commun. 1998;6(2-3):157-60 PMID: 9823467
  87. No evidence for cancer-related CD44 splice variants in primary and metastatic colorectal cancer.
    Eur J Cancer. 1998 Jun;34(7):1099-1104 PMID: 9849461
  88. Disorderly CD44 gene expression in human cancer cells can be modulated by growth conditions.
    J Pathol. 1998 Sep;186(1):17-23 PMID: 9875135
  89. Identification of two regions in the cytoplasmic domain of CD44 through which PMA, calcium, and foskolin differentially regulate the binding of CD44 to hyaluronic acid.
    Cell Immunol. 1998 Dec 15;190(2):132-40 PMID: 9878114
  90. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
    Clin Cancer Res. 1997 Sep;3(9):1629-34 PMID: 9815853
  91. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons.
    Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12160-4 PMID: 1465456
  92. Prevention of tumor metastasis formation by anti-variant CD44.
    J Exp Med. 1993 Feb 1;177(2):443-55 PMID: 8426113
  93. The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: each one individually suffices to confer metastatic behavior.
    Cancer Res. 1993 Mar 15;53(6):1262-8 PMID: 8443806
  94. Splicing choice from ten variant exons establishes CD44 variability.
    Nucleic Acids Res. 1993 Mar 11;21(5):1225-9 PMID: 8464707
  95. The identification of a new alternative exon with highly restricted tissue expression in transcripts encoding the mouse Pgp-1 (CD44) homing receptor. Comparison of all 10 variable exons between mouse, human, and rat.
    J Biol Chem. 1993 Jun 15;268(17):12235-8 PMID: 8509359
  96. Identification of hyaluronic acid binding sites in the extracellular domain of CD44.
    J Cell Biol. 1993 Jul;122(1):257-64 PMID: 8314845
  97. Antibody-induced activation of the hyaluronan receptor function of CD44 requires multivalent binding by antibody.
    Eur J Immunol. 1993 Aug;23(8):1902-9 PMID: 7688309
  98. CD44 and its interaction with extracellular matrix.
    Adv Immunol. 1993;54:271-335 PMID: 8379464
  99. Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies.
    Blood. 1993 Dec 15;82(12):3539-47 PMID: 7505117
  100. A PCR-based method for the analysis of human CD44 splice products.
    PCR Methods Appl. 1993 Oct;3(2):100-6 PMID: 7505677
  101. Expression and modulation of CD44 variant isoforms in humans.
    J Cell Biol. 1994 Jan;124(1-2):71-82 PMID: 7507492
  102. Identification of a common hyaluronan binding motif in the hyaluronan binding proteins RHAMM, CD44 and link protein.
    EMBO J. 1994 Jan 15;13(2):286-96 PMID: 7508860
  103. Non-invasive detection of malignancy by identification of unusual CD44 gene activity in exfoliated cancer cells.
    BMJ. 1994 Mar 5;308(6929):619-24 PMID: 8148709
  104. Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development.
    J Exp Med. 1994 Jul 1;180(1):53-66 PMID: 7516417
  105. A novel ligand for CD44 is sulfated proteoglycan.
    Int Immunol. 1994 Apr;6(4):655-60 PMID: 7517179
  106. ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons.
    J Cell Biol. 1994 Jul;126(2):391-401 PMID: 7518464
  107. Ankyrin-binding domain of CD44(GP85) is required for the expression of hyaluronic acid-mediated adhesion function.
    J Cell Biol. 1994 Aug;126(4):1099-109 PMID: 7519619
  108. CD44 variant isoforms are preferentially expressed in basal epithelial of non-malignant human fetal and adult tissues.
    Histochemistry. 1994 Feb;101(2):79-89 PMID: 7520892
  109. Characterization of soluble CD44 in the circulation of mice. Levels are affected by immune activity and tumor growth.
    J Immunol. 1994 Oct 15;153(8):3440-9 PMID: 7523494
  110. New CD44 splice variants associated with human breast cancers.
    J Cell Physiol. 1995 Jan;162(1):127-33 PMID: 7529235
  111. Expression of CD44 splice variants during lymphocyte activation and tumor progression.
    Cell Adhes Commun. 1994 Jul;2(3):195-200 PMID: 7530151
  112. Significance of CD44 gene products for cancer diagnosis and disease evaluation.
    Lancet. 1992 Oct 31;340(8827):1053-8 PMID: 1357452
  113. CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor.
    J Cell Biol. 1995 Feb;128(4):687-98 PMID: 7532176
  114. Role of CD44 cytoplasmic domain in hyaluronan binding.
    Eur J Immunol. 1995 Feb;25(2):495-501 PMID: 7533087
Article Info
Journal
Molecular pathology : MP
Abbr.
Mol Pathol
ISSN
1366-8714
Published
1999-08-00
Pages
189-96
Language
English
Region
England
NLM ID
9706282
PMCID
PMC395698
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com